AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 311 min read$ICUI

Bonnell Brian Michael sold $1.6M of ICUI

Bonnell Brian Michael (Chief Financial Officer) sold 9,307 shares of ICU MEDICAL INC/DE (ICUI) at an average of $172.79 ($171.05–$173.91, $1.61M total) across 4 trades on 2026-08-31 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Bonnell Brian Michael
Published Aug 31, 2026, 8:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 31, 2026, 8:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ICUI
Neutral
medium confidence
Mentioned
$ICUI
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ICUINeutralLow
01

Why it matters

The disclosed sale provides fresh data on insider sentiment for ICU Medical.

02

Market read

First public disclosure of a CFO's $1.6M share sale; modest relevance for traders monitoring insider activity.

03

What to watch

The CFO retains 62,443 shares, indicating continued stake.

Relevance 5/10Novelty 7/10Timing: 2026-08-31 filing

Background

SEC Form 4 filing discloses insider transactions.

Company-level read

Ticker impact

$ICUINeutralMedium confidence
Context

CFO Bonnell Brian Michael sold $1.6M of ICUI shares via a 10b5-1 plan on 2026-08-31.

Expected impact

Potential modest downside pressure as market digests the sale.

Evidence & confidence

A $1.6M sale by a senior officer is material for a mid‑cap biotech, but not large enough to trigger a sharp move.

Market effects

Sector

May raise questions about CFO's view on ICU Medical's near‑term prospects.

Regional

Limited to US biotech investors.

Global

Minimal.

Counterpoint

What could challenge this read

The sale could be routine under a pre‑arranged plan, not a negative signal.

Key entities

  • Company
    ICU Medical Inc.

    Medical device manufacturer listed on Nasdaq (ICUI).

  • Executive
    Bonnell Brian Michael

    Chief Financial Officer of ICU Medical.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ICUI insider trading history →

Related articles

AUG 27
$ICUIMed

ICU Medical rating upgraded by S&P on stronger credit metrics

S&P Global Ratings upgraded ICU Medical Inc. to 'BB' from 'BB-', citing improved credit metrics and strong operating performance. The company's adjusted leverage decreased to 3.1x in Q2 2026, with free operating cash flow exceeding expectations. ICU Medical used proceeds from asset sales and cash flow to reduce debt. S&P projects mid-single-digit revenue growth and margin improvement through 2027, with a stable outlook based on expected debt and cash flow metrics.

investing.com2 min
AUG 14
$ICUIMedAI 8/10

ICU Medical (ICUI) Q2 2026 Earnings Call Transcript

ICU Medical (ICUI) reported Q2 2026 revenue of $551.7M, up 1% reported and 6% organic excluding IV Solutions divestiture and currency. Infusion Systems revenue was $189.0M (+12% organic), Consumables $289.3M (+5% organic). Adjusted EBITDA was $110.0M (+10%). Full-year guidance raised to $415M-$435M EBITDA and $8.60-$9.00 EPS.

fool.com7 min
AUG 10
$ICUIHighAI 9/10

ICU Medical (ICUI) Shares Skyrocket, What You Need To Know

ICU Medical (NASDAQ:ICUI) shares rose 10.2% after the company reported Q2 results that beat Wall Street and lifted full-year guidance. Adjusted EPS was $2.37 vs $1.91 expected, revenue was $551.7 million vs forecasts, and free cash flow improved to $61.64 million. Full-year adjusted EPS guidance was raised to $8.80 (midpoint).

finance.yahoo.com4 min
AUG 7
$ICUIHighAI 9/10

ICU Medical (ICUI) Shares Skyrocket, What You Need To Know

ICU Medical (NASDAQ: ICUI) shares rose 10.2% after the company reported Q2 adjusted EPS of $2.37, above the $1.91 consensus, and revenue of $551.7 million, above forecasts. Free cash flow improved to $61.64 million from -$8.49 million a year earlier. ICU Medical raised full-year adjusted earnings guidance to $8.80 per share (midpoint).

financialcontent.com3 min
AUG 6
$ICUIMedAI 8/10

ICU Medical (NASDAQ:ICUI) Reports Strong Q2 CY2026

ICU Medical (NASDAQ:ICUI) reported Q2 CY2026 results. Revenue rose 1.5% year over year to $551.7 million, beating Wall Street’s revenue estimate by 3.5%. Non-GAAP adjusted EPS was $2.37, up from $2.10 and 23.8% above consensus. The stock rose 1.4% to $168.02 after the release.

financialcontent.com4 min